Cite
HARVARD Citation
Clark, J. et al. (n.d.). A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01). Journal for immunotherapy of cancer. p. . [Online].